EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort

Paula Olivares-Navarro, María Teresa Pérez-Rodríguez, Adrián Sousa, Ane Josune Goikoetxea-Agirre, María José Blanco Vidal, Antonio Plata, Eva León, Luis Buzón-Martín, Ángeles Pulido-Navazo, Lucía Boix-Palop, Pilar Retamar-Gentil, Carlos Armiñanzas-Castillo, Isabel Fernández-Natal, Alfonso Del Arco Jiménez, Alfredo Jover-Sáenz, Jonathan Fernández-Suárez, Andrés Martín-Aspas, Alejandro Smithson-Amat, Alberto Bahamonde-Carrasco, Clara Natera-Kindelán, Pedro María Martínez Pérez-Crespo, Inmaculada López-Hernández, Jesús Rodríguez-Baño, Luis Eduardo López-Cortés, José María Reguera-Iglesias, José María Bravo-Ferrer, Antonio Sánchez-Porto, Juan Manuel Sánchez-Calvo, Isabel Reche, Isabel Gea-Lázaro, David Vinuesa-García, Inés Pérez-Camacho, Marcos Guzmán-García, Esperanza Merino de Lucas

Journal of Antimicrobial Chemotherapy · 2026-04-03 · 81 (5)

DOI: 10.1093/jac/dkag130 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objective The incidence of bloodstream infection (BSIs) due to extended-spectrum β-lactamase (ESBL) producing Escherichia coli is increasing worldwide. There is controversy as to whether ESBL production in itself is associated with higher mortality. The aim of this study is to evaluate the impact of ESBL production on mortality in BSIs due to E. coli considering the effect of confounders. Methods PROBAC study is a prospective, multicentre, cohort study performed in 26 Spanish hospitals (October 2016–March 2017). All patients with E. coli BSIs were included. The outcome variable was all-cause 30-day mortality. Confounding was controlled by calculating a propensity score (PS) for ESBL production using baseline variables. PS were used as covariable, for matching, for inverse probability of treatment weight analysis and for stratified analysis within the PS quartiles. Results A total of 2394 cases were included, of which 322 (13.5%) were ESBL-producing isolates. The frequency of appropriate empirical treatment, in ESBL-producing and non-ESBL-producing isolates, was 53.7% and 92.0%, respectively. Thirty-day mortality was 14.6% in ESBL-producing isolates versus 9.6% in non-ESBL-producing isolates (P = 0.006), for a crude OR of 1.61 (95% CI: 1.14–2.27; P = 0.006). When we adjusted by PS and appropriate empirical treatment, the OR changed to 1.12 (95% CI: 0.75–1.67; P = 0.584). Other PS applications provided similar results. Conclusion BSIs due to ESBL-producing E. coli were associated with higher mortality in the crude analyses; however, the estimate of the association is reduced after adjustment for baseline variables and empirical therapy, and is not significant in matched analysis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →